599 related articles for article (PubMed ID: 10470218)
1. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
2. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
3. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
4. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
5. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
8. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
10. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
Oremek GM; Sapoutzis N
Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
[TBL] [Abstract][Full Text] [Related]
12. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
13. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
Miyake Y; Kodama T; Yamaguchi K
Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
[TBL] [Abstract][Full Text] [Related]
14. ProGRP: a new biomarker for small cell lung cancer.
Molina R; Filella X; Augé JM
Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
[TBL] [Abstract][Full Text] [Related]
15. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
Yang J; Li R; Li A
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
[TBL] [Abstract][Full Text] [Related]
17. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
18. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
19. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]